

Supplementary Table S1. DMARD therapy for different visits.

Medication	Initial visit n=136*	Remission visit* n=109	Clinical visit n=136*
Prednisolone, n (%)	100 (73.5)	71 (65.1)	53 (39.0)
csDMARD	99 (72.8)	88 (80.7)	93 (68.4)
bDMARD	18 (13.2)	45 (41.3)	63 (46.3)
tsDMARD	2 (1.5)	2 (1.8)	17 (12.5)
TNF α	12 (8.8)	30 (27.5)	31 (22.8)
IL6-antagonists	3 (2.2)	5 (4.6)	9 (6.6)
Methotrexate	82 (60.3)	79 (72.5)	83 (61.0)
Hydroxychloroquin	6 (4.4)	3 (2.8)	3 (2.2)
Sulfasalazin	6 (4.4)	5 (4.6)	6 (4.4)
Azathioprin	2 (1.5)	1 (0.9)	0
Leflunomid	7 (5.1)	2 (1.8)	10 (7.4)
Tofacitinib	1 (0.7)	2 (1.8)	2 (1.5)
Upadacitinib	0	0	1 (0.7)
Baricitinib	1 (0.7)	0	14 (10.3)
Etanercept	7 (5.1)	14 (12.8)	13 (9.6)
Infliximab	1 (0.7)	1 (0.9)	1 (0.7)
Adalimumab	0	4 (3.7)	7 (5.1)
Golimumab	1 (0.7)	2 (1.8)	2 (1.5)
Certolizumab	3 (2.2)	9 (8.3)	7 (5.1)
Abatacept	2 (1.5)	5 (4.6)	14 (10.3)
Rituximab	1 (0.7)	4 (3.7)	8 (5.9)
Anakinra	0	1 (0.9)	2 (1.5)
Sarilumab	0	3 (2.8)	5 (3.7)
Tocilizumab	3 (2.2)	2 (1.8)	3 (2.2)
Cyclophosphamide	0	0	0

* n (%).